Mr. Alejandro Antalich reports

EVOKAI CREATIVE LABS TO ACQUIRE AI-POWERED COMPANY REHABOO OY

EvokAI Creative Labs Inc. has entered into a definitive agreement dated effective May 2, 2023, which was negotiated at arm's length, pursuant to which the company intends to acquire all the issued and outstanding securities of Rehaboo Oy. Rehaboo's main product is a versatile physical gamification platform based on high-definition motion-sensing technology, powered by AI to promote an active lifestyle and brain health in any environment.

Following the closing of the Rehaboo acquisition, Rehaboo will be a wholly owned subsidiary of EvokAI. Completion of the Rehaboo Acquisition is subject to a number of standard conditions, including receipt of all regulatory approvals and the acceptance of the TSX Venture Exchange ("TSXV"). The Rehaboo Acquisition is expected to close on or about May 24, 2023.

"As part of our rapid evolution to become a global HUB for brain health, this acquisition will allow us to unlock short-term fast growth going beyond patients, the current segment covered by EvokAI, creating limitless opportunities to billions of healthy individuals, occupational healthcare, private and public healthcare service providers, insurance and pharmaceutical companies, among others. Gamification has become a key element in empowering human beings to achieve desired outcomes for brain and body health, and Rehaboo provides an increasingly exciting set of value-added non-invasive solutions to meet EvokAI's current and new customer's needs," said Alejandro Antalich, CEO and Director of EvokAI Creative Labs.

Rehaboo is a private company founded on November 28, 2016 under the laws of Finland after winning the "Happier Hospital" health track Slush Hacks hackathon organized by GE Healthcare and the new Helsinki University Children's Hospital. Rehaboo's Active cloud-based AI gaming platform is a solution that analyzes, learns, improves, and predicts from players' movement and cognitive activation. It is currently being used at hospitals, elderly care homes, and as a home care solution in tens of locations in Finland and Denmark, also in research pilots in Singapore and Oslo, Norway. Rehaboo's platform has potential to tackle the burden of several diseases associated with cognitive functions and inactivity. In addition, the platform provides vast improvement in home care through accessibility and by creating a sort of metaverse for elderly generation, where players can exercise while joining a playful competition with an avatar.

Created by renowned neuroscientists and physical therapy professionals, Rehaboo's platform improves blood flow to the brain and cognitive functions, whilst promoting the growth of new brain cells. Its uniqueness, easy to scale and novel algorithms provide data analytics, real-time feedback and progress tracking. Most relevant is the platform's ability to adapt according to users' capabilities. It analyzes movements and provides personalized feedback on form and technique, also adjusting the difficulty level based on the user's performance.

"This combination strengthens our capabilities of achieving our original vision: to fight inactivity with gamification. EvokAI's AI-based platform has potential to improve availability and to develop Rehaboo's solution to become even more engaging, efficient, and personalized according to different users' needs by leveraging the power of machine learning and high-performance GPUs for various devices. This allows us to create accessible new and engaging motion sensing games worldwide, without any wearable devices or extra accessories. Furthermore, our algorithms can also help to prevent injuries by monitoring each user's movements and detecting potential risks or imbalances, suggesting corrective movements to prevent further injuries or damages," commented Peter Green, Founder and CEO of Rehaboo.

"AI and machine learning are paving the way for revolutionary advancements in brain health, empowering individuals to take control of their cognitive well-being from the comfort of their homes," says Taneli Tikka, EvokAI's Tech Advisor and investor of Rehaboo. "Maintaining a healthy brain will be more pleasant and appealing through good technology and improved customer experience," he added.

Rehaboo's unique cloud-based solution is using NVIDIA GPU in conjunction with the TensorFlow machine learning framework along with novel algorithms. The platform is available on any "normal" digital device, such as a personal computer, mobile phone, tablet, or internet enabled TV, since it runs in the cloud to maximize accessibility. A hyper-scalable aspect of Rehaboo, is the innovative solution that users' own bodies function as the game controllers. Artificial intelligence recognizes and analyzes body movements registered by a standard webcam. Hence, no separate controls are required, and accessibility is further improved.

For more information about Rehaboo, visit the company's website at rehaboo.com.

Pursuant to the terms of the Share Purchase Agreement, holders of 100% of Rehaboos' common shares ("Rehaboo Shares") will be issued common shares of the Company (the "Shares") having an aggregate value of US$4,000,000, at a price determined by the average closing price of the Shares over a period of 16 trading days commencing May 2, 2023, subject to certain minimums and maximums, as consideration in exchange for their Rehaboo Shares. The Shares issued will be subject to an agreed hold period ending on November 30, 2023.

About EvokAI Creative Labs Inc.

EvokAI is a MedTech AI-powered company dedicated to the development of transformational and innovative technologies for the modern healthcare sector. We deploy machine learning models to search medical data and uncover insights to help improve health outcomes, patient experiences, drug development, preclinical and clinical decisions and provide more accurate diagnoses. EvokAI tailors its AI algorithms across the whole healthcare system, from hospitals, private clinics, research institutions, pharmaceutical companies, contract research organizations, to medical professionals, patients, healthy individuals aiming at preventing any kind of disease and beyond, protecting the aging genome.

We seek Safe Harbor.